HRMY
Harmony Biosciences is a commercial-stage neuroscience company focused on rare neurological diseases across sleep/wake disorders, rare epilepsy, and neurobehavioral indications using small molecule therapeutics. Its lead product WAKIX (pitolisant), a first-in-class H3 receptor antagonist/inverse agonist, is FDA-approved for excessive daytime sleepiness and cataplexy in narcolepsy across adult and pediatric populations, and the company has late-stage clinical programs evaluating pitolisant in idiopathic hypersomnia, Prader-Willi syndrome, and myotonic dystrophy type 1. Harmony is also advancing next-generation pitolisant formulations (Pitolisant GR and Pitolisant HD) in clinical development, an orexin 2 receptor agonist (BP1.15205) in preclinical